Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advisory Committee To Revisit Boxed Warning For Protopic, Elidel

This article was originally published in The Pink Sheet Daily

Executive Summary

Six years after recommending boxed warnings and medication guides for Novartis' Elidel (pimecrolimus) and Astellas' Protopic (tacrolimus), the Pediatric Advisory Committee will hear updates on their safety.

You may also be interested in...



Sub-therapeutic Dosing In Pediatric Trials To Be Reviewed By FDA's Pediatric Ethics Subcommittee

Panel is called in to shed light in a growing but still controversial area.

Sub-therapeutic Dosing In Pediatric Trials To Be Reviewed By FDA's Pediatric Ethics Subcommittee

Panel is called in to shed light in a growing but still controversial area.

"Black Box" For Protopic, Elidel Is "Blunt" But Necessary Instrument, Advisory Cmte. Says

Although noting that data suggesting a cancer risk from the topical eczema treatments is not definitive, the panel concludes that a black box warning is the best approach to discourage off-label use. A medication guide should also be mandated, the committee says.

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel